Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: A multicenter study in a community-based environment

Journal of Neurology

Volumn 259, Issue 11, 2012, Pages 2347-2353

  Bischoff, Christian ^a   Schreiber, H ^b   Bergmann, A ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Neurologische Gemeinschaftspraxis and Neuropoint Patient Academy   (Germany)

^c Neurologische Praxis ^*  (Germany)

Author keywords

Adherence; Drug therapy; Immunomodulatory therapy; Interferons; Multiple sclerosis

Indexed keywords

IMMUNOMODULATING AGENT;

ADULT; ARTICLE; COMMUNITY; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG WITHDRAWAL; EMPATHY; FATIGUE; FEAR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NURSE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT DECISION MAKING; PATIENT INFORMATION; PHYSICIAN; PRIORITY JOURNAL; SEX; TREATMENT DURATION; TREATMENT WITHDRAWAL;

ADULT; AMBULATORY CARE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIPLE SCLEROSIS; RESIDENCE CHARACTERISTICS; SOCIAL ENVIRONMENT;

EID: 84868194715     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6499-1     Document Type: Article

References (29)

1. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343:898-904
2. Comi G, Filipi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. The Lancet 357:1576-1582 (Pubitemid 32488815)
3. Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH et al (2006) Treatment with interferon-beta1b delays conversion to clinically definite and Mc Donald MS in patients with clinically isolated syndromes. Neurology 67:1242-1249 (Pubitemid 44563835)
4. Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O (2010) Effect of glaterimere acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 375:1436
5. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899-910
6. Klauer T, Zettl UK (2008) Compliance, adherence, and the treatment of multiple sclerosis. J Neurol 255(6):87-92
7. Kern S, Reichmann H, Ziemssen T (2008) Adherence to neurologic treatment: lessons from multiple sclerosis. Nervenarzt 79:884-8868
8. Steinberg SC, Faris RJ, Chang CF, Chan A, Tankersley MA (2010) Impact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort study. Clin Drug Invest 30:89-100
9. O'Rourke KE, Hutchinson M (2005) Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mult Scler 11:46-50 (Pubitemid 40259974)
10. Tremlett HL, Oger J (2003) Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS. Neurology 61:551-554 (Pubitemid 37025380)
11. Kern S, Reichmann H, Ziemssen T (2008) Therapieadhärenz in der neurologischen Praxis. Nervenarzt 79:877-890
12. Kleinman NL, Beren IA, Rajagopalan K, Brook RA (2010) Medication adherence with disease modifying treatments for multiple sclerosis among US employees. J Med Economics 13:633-640
13. Wong J, Gomes T, Mamdani M, Manno M, O'Connor PW (2011) Adherence to multiple sclerosis disease-modifying therapies in Ontario is low. Can J Neurol Sci 38:429-433
14. PharMetrics Patient-Centric Database. Jan 2000-Mar 2002 data on file. http://www.phrma.org/publications/policy/2002.pdf (download am 21.07.2005)
15. Arroyo E, Grau C, Ramo-Tello C, Parra J, Sanchez-Solino O (2011) Adherence to disease-modifying therapies in Spanish patients with relapsing multiple sclerosis: two-year interim analysis of the global adherence project. Eur Neurol 65:59-67
16. Portaccio E, Zipoli V, Siracusa G, Sorbi S, Amato MP (2008) Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis. Eur Neurol 59:131-135 (Pubitemid 351301255)
17. Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, Suchet L, Kieseier BC (2011) The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 18:69-77
18. Zwibel H, Pardo G, Smith S, Denney D, Oleen-Burkey M (2011) A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment for treatment of relapsing-remitting multiple sclerosis. J Neurol 258:402-411
19. Goodkin DE, Hertsgaard D, Rudick RA (1989) Exacerbation rates and adherence to a disease type in a prospectively followed-up population with multiple sclerosis: implications for clinical trials. Arch Neurol 46:1107-1112 (Pubitemid 19246301)
20. Treadaway K, Cutter G, Salter A, Lynch S, Simsarian J, Corboy J (2009) Factors that influence adherence with disease-modifying therapy in MS. J Neurol 256:568-576
21. Bruce JM, Hancock LM, Arnett P, Lynch S (2010) Treatment adherence in multiple sclerosis: association with emotional status, personality and cognition. J Behav Med 33:219-227
22. Bruce JM, Hancock LM, Lynch SG (2009) Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult Scler 16:112-120
23. Anderson LA (1990) Health-care communication and selected psychosocial correlates of adherence in diabetes management. Diabetes Care 3:66-76 (Pubitemid 20050015)
24. Vermeire E, Hearnshaw H, Van Royen P, Denekens J (2001) Patient adherence to treatment: three decades of research: a comprehensive review. J Clin Pharm Ther 26:331-342 (Pubitemid 32989555)
25. Runmarker B, Anderson O (1993) Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116:117-134 (Pubitemid 23087038)
26. Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770-782 (Pubitemid 36372978)
27. Hancock LM, Bruce JM, Lynch SG (2011) Exacerbation history is associated with medication and appointment adherence in MS. J Behav Med 34:330-338
28. Ries S, Elias WG, Japp G, Lang M (2008) Steigerung der Therapietreue durch ein Therapiebegleitprogramm bei Multipler Sklerose. Nervenheilkunde 27:818-822
29. Stöckl KM, Shin JS, Gong S, Harada AS, Solow BK, Lew HC (2010) Improving patient self-management of multiple sclerosis through a disease therapy management program. Am J Manag Care 16:139-144